A&M Perspectives: How asset light pharmaceutical companies can augment value creation in a disrupted market environment
Over the past two decades, originator pharmaceutical businesses have increasingly disposed of late-stage drug portfolios to third parties. This has spurred the growth of asset-light pharmaceutical companies with radically different operating models. Operating through networks of Contract Development and Manufacturing Organisations (CDMOs), these businesses avoid major capital expenditure, have greater flexibility, and can therefore focus on critical capabilities such as supply chain excellence, market authorisation and technical transfers.
While there are advantages, asset-light models are complex. Many different partners are involved, comprising of specialised CDMOs, distribution partners and a mix of in-house sales and country distributors. This leads to challenges related to demand planning, inventory control and cost control.
At the same time, asset-light pharma businesses are having to respond to global challenges including rising inflation, supply chain disruptions, Covid-19 outbreaks and growing geopolitical tensions.
Based on our experiences of delivering change for a range of asset-light pharmaceutical companies across Europe, we recommend five levers of value creation.
Five value levers for asset-light pharmaceutical businesses
- CDMO rationalisation and technical transfer excellence
- S&OP/ IBP upgrades
- Inventory and working capital optimisation
- Logistics simplification
- Digital tools deployment (commercial focus)
Download
Related Insights
Shocks to global supply chains are increasing in frequency and severity. Russia’s invasion of Ukraine, new Covid outbreaks in China and rising interest rates in the US are occurring at once with ramifications for global trade. What steps can companies take to improve supply chain resilience.
ALVAREZ & MARSAL SCALES HEALTHCARE PRACTICE WITH FOUR STRATEGIC HIRES FOCUSED ON HEALTH PLANS AND MANAGED CARE
July 28, 2025
Leading global professional services firm Alvarez & Marsal (A&M) today announced significant expansion within its Health Plans and Managed Care practice. Joining the firm are Managing Directors Michael Epstein and Jim Collier, alongside Senior Directors Brent Hill and Todd Masser, enhancing A&M’s capability to deliver tailored, actionable solutions driving client growth.
The Rise of Alternative Health Coverage Models: Short-Term Duration Plans, Health Care Sharing Ministries, and ICHRAs
July 24, 2025
Explore the surge in alternative coverage models, Short-Term Duration Plans, Health Care Sharing Ministries, and ICHRAs that operate outside traditional ACA-compliant insurance. With deregulation on the rise and federal funding shifts ahead, understanding their structure and policy exposure is essential.
Alvarez & Marsal Expands Its Healthcare Human Capital and Workforce Management Offering
July 17, 2025
A&M appoints Felicia Lyon as a Managing Director in the firm’s Healthcare Industry Group, specializing in Human Capital and Workforce Management.
Alvarez & Marsal (A&M) and Alston & Bird Release Landmark Governance Report Urging Health Systems to Fortify Board Oversight in Light of Federal Healthcare Cuts
July 15, 2025
Alvarez & Marsal (A&M) and Alston & Bird released the Governance of High-Performing Nonprofit Hospital Systems report - a survey of 17 leading nonprofit health systems. The report outlines the best practices in board governance and warns of consequences for inaction.
